Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.
Amphotericin B in combination with 5-fluorocytosine was synergistic against three clinical isolates of Aspergillus fumigatus and one of three clinical isolates of A. flavus. Amphotericin B in combination with rifampin was synergistic against all six clinical isolates of Aspergillus tested. The levels of 5-fluorocytosine and rifampin required for synergism were higher than clinically achievable concentrations when measurements of synergism were based on visual turbidity; but when the effects of the drugs were measured by inhibition of ribonucleic acid synthesis or dry-weight increase, much lower concentrations were effective.
D000666:Amphotericin B / Q000494:pharmacology*; D001230:Aspergillus / Q000378:metabolism; D001231:Aspergillus flavus / Q000187:drug effects*; D001232:Aspergillus fumigatus / Q000187:drug effects*; D003596:Cytosine / Q000031:analogs & derivatives*; D005437:Flucytosine / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D012313:RNA / Q000096:biosynthesis; D012293:Rifampin / Q000494:pharmacology*; D014529:Uridine / Q000378:metabolism
D012313:RNA; D000666:Amphotericin B; D003596:Cytosine; D005437:Flucytosine; D012293:Rifampin; D014529:Uridine